Shilpa Medicare Limited Fundamental Analysis
Shilpa Medicare Limited Fundamental Analysis
Shilpa Medicare Limited (SHILPAMED.BO) shows weak financial fundamentals with a PE ratio of 47.52, profit margin of 15.82%, and ROE of 9.97%. The company generates $7.7B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 61.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze SHILPAMED.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakSHILPAMED.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateSHILPAMED.BO shows balanced valuation metrics.
Growth Score
ModerateSHILPAMED.BO shows steady but slowing expansion.
Financial Health Score
ExcellentSHILPAMED.BO maintains a strong and stable balance sheet.
Profitability Score
ModerateSHILPAMED.BO maintains healthy but balanced margins.
Key Financial Metrics
Is SHILPAMED.BO Expensive or Cheap?
P/E Ratio
SHILPAMED.BO trades at 47.52 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SHILPAMED.BO's PEG of 0.23 indicates potential undervaluation.
Price to Book
The market values Shilpa Medicare Limited at 4.46 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 25.51 times EBITDA. This signals the market has high growth expectations.
How Well Does SHILPAMED.BO Make Money?
Net Profit Margin
For every $100 in sales, Shilpa Medicare Limited keeps $15.82 as profit after all expenses.
Operating Margin
Core operations generate 20.43 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.97 in profit for every $100 of shareholder equity.
ROA
Shilpa Medicare Limited generates $6.57 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Shilpa Medicare Limited produces operating cash flow of $1.01B, showing steady but balanced cash generation.
Free Cash Flow
Shilpa Medicare Limited generates weak or negative free cash flow of $192.29M, restricting financial flexibility.
FCF Per Share
Each share generates $1.97 in free cash annually.
FCF Yield
SHILPAMED.BO converts 0.33% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
47.52
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.23
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.46
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.52
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.31
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How SHILPAMED.BO Stacks Against Its Sector Peers
| Metric | SHILPAMED.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 47.52 | 33.92 | Worse (Expensive) |
| ROE | 9.97% | 393.00% | Weak |
| Net Margin | 15.82% | -41456.00% (disorted) | Strong |
| Debt/Equity | 0.25 | 0.80 | Strong (Low Leverage) |
| Current Ratio | 1.31 | 4.57 | Neutral |
| ROA | 6.57% | -293.00% (disorted) | Weak |
SHILPAMED.BO outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Shilpa Medicare Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation